A new class of injectable medications that mimic and amplify the body’s own appetite-regulating hormones has fundamentally altered the treatment landscape for obesity and type 2 diabetes, drawing both widespread clinical enthusiasm and pointed debate over equitable access. Drugs such as tirzepatide, sold under the brand name Mounjaro, and semaglutide, marketed for weight management as Wegovy, have demonstrated weight loss outcomes in clinical trials that were previously achievable only through bariatric surgery, prompting health systems and insurers worldwide to grapple with how to incorporate them into their formularies responsibly.
Both drugs belong to a family of medications that act on hormones produced naturally in the gut in response to food intake. Tirzepatide is a dual agonist, meaning it activates receptors for two hormones simultaneously: glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, known as GIP. Semaglutide is a GLP-1 receptor agonist only. GLP-1 is released by cells in the small intestine after eating and performs several functions relevant to weight and blood sugar regulation: it stimulates the pancreas to release insulin in proportion to blood glucose levels, suppresses the release of glucagon, slows the rate at which the stomach empties, and signals to the brain that the body has consumed sufficient food. GIP works through a related but distinct receptor and appears to enhance some of the metabolic effects produced by GLP-1 activation alone.
In practical terms, the medications reduce appetite significantly, alter food preferences in ways that many patients describe as a “quieting” of food cravings, and slow gastric emptying so that meals produce a prolonged sense of fullness. Clinical trial data for tirzepatide, published in major endocrinology journals, showed average weight reductions of 20 to 22 percent of total body weight over 72 weeks among participants with obesity who did not have diabetes, results that exceeded those seen in earlier semaglutide trials, where average loss hovered at approximately 15 percent. Both figures substantially outperform older weight-loss medications, most of which produced average reductions below 10 percent.
“What we are seeing is genuinely unprecedented in pharmacological obesity treatment,” said Dr. Randolph Achebe, an endocrinologist at a university hospital in Toronto who has enrolled more than 200 patients in weight management programs involving the new drug class. “For the first time we have medications that produce durable, clinically meaningful weight loss at a magnitude that can reduce cardiovascular risk, improve glycaemic control, and in some patients reverse early metabolic disease.” He cautioned, however, that the drugs are not without side effects: nausea, vomiting, and diarrhea are common, particularly during the dose-escalation phase, and rare but serious complications including pancreatitis and changes in heart rate have been reported.
The mechanisms of action also raise questions about long-term use. Because the drugs work primarily by suppressing appetite through hormonal signaling, weight tends to return when the medication is discontinued, a pattern documented in follow-up studies that tracked patients for a year or more after stopping treatment. This has led to growing clinical consensus that for many patients, these drugs represent a chronic medication rather than a finite course of therapy, a consideration that significantly affects their cost-effectiveness and sustainability within health systems operating under budget constraints.
The price of the medications has emerged as a central point of controversy. In the United States, a monthly supply of either drug can cost upward of $1,000 to $1,300 without insurance coverage, placing them out of reach for many patients who might benefit most — including those in lower-income brackets where obesity prevalence is disproportionately high. Public and private insurers have taken divergent approaches, with some covering the drugs broadly for qualifying patients and others limiting coverage to those with documented type 2 diabetes, effectively excluding coverage for obesity alone. Patient advocacy organizations have argued that this distinction reflects an outdated perception of obesity as a lifestyle choice rather than a chronic disease with complex biological underpinnings.
Research into next-generation compounds is already underway. Several pharmaceutical companies have drugs in late-stage trials that target additional hormonal pathways, including a triple agonist that adds glucagon receptor activation to the GLP-1 and GIP targets, with early data suggesting even greater weight loss potential. Scientists are also investigating whether the drugs’ anti-inflammatory properties may confer benefits in conditions beyond metabolic disease, including non-alcoholic fatty liver disease and certain cardiovascular conditions.
Health economists and policy analysts emphasize that the drugs’ full societal value — including reductions in downstream costs associated with obesity-related conditions such as heart disease, sleep apnea, and joint disease — must be factored into coverage decisions. Several modeling studies have concluded that broad coverage of GLP-1 class medications is likely to be cost-effective over a 10-year horizon when accounting for avoided hospitalizations and procedures. Whether those projections translate into faster and more equitable access remains a question that health systems across multiple countries are actively working to resolve.